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Cerebral amyloid angiopathy (CAA) is a key histopathological hallmark of Alzheimer’s disease (AD) and
hereditary cerebral hemorrhage with amyloidosis of the Dutch type (HCHWA-D). CAA is characterized by
amyloid-beta (Ab) depositions and remodeling of the extracellular matrix (ECM) in brain vessels and
plays an important role in the development and progression of both AD and HCHWA-D. Tissue trans-
glutaminase (tTG) modulates the ECM by molecular cross-linking of ECM proteins. Here, we investigated
the distribution pattern, cellular source, and activity of tTG in CAA in control, AD, and HCHWA-D cases.
We observed increased tTG immunoreactivity and colocalization with Ab in the vessel wall in early stage
CAA, whereas in later CAA stages, tTG and its cross-links were present in halos enclosing the Ab
deposition. In CAA, tTG and its cross-links at the abluminal side of the vessel were demonstrated to be
either of astrocytic origin in parenchymal vessels, of ﬁbroblastic origin in leptomeningeal vessels, and of
endothelial origin at the luminal side of the deposited Ab. Furthermore, the ECM proteins ﬁbronectin and
laminin colocalized with the tTG-positive halos surrounding the deposited Ab in CAA. However, we
observed that in situ tTG activity was present throughout the vessel wall in late stage CAA. Together, our
data suggest that tTG and its activity might play a differential role in the development and progression of
CAA, possibly evolving from direct modulation of Ab aggregation to cross-linking of ECM proteins
resulting in ECM restructuring.
 2013 Elsevier Inc. Open access under the Elsevier OA license.1. Introduction
Alzheimer’s disease (AD) is a neurodegenerative disorder char-
acterized by deposition of amyloid-beta (Ab) peptide aggregates in
the brain. In the parenchyma, Ab aggregates in the form of senile
plaques (SPs), whereas Ab deposition in the vasculature results in
cerebral amyloid angiopathy (CAA) (Selkoe, 1994). The Ab protein is
a proteolytic cleavage product of the amyloid precursor protein and
is produced in 2 major forms (Ab1e40 and Ab1e42), both capable of
interacting with themselves which results in toxic Ab aggregates
(Walsh et al., 1999). SPs mainly consist of Ab1e42, whereas Ab1e40
is the major component of CAA (Attems et al., 2011). CAA is present
in more than 90% of all AD patients (Jellinger and Attems, 2005)
and is also the major pathologic hallmark in patients with heredi-
tary cerebral hemorrhage with amyloidosis of the Dutch typeical Center, Department of
7, 1081 BT Amsterdam, The
100.
.
evier OA license.(HCHWA-D). HCHWA-D is characterized by the E22Q mutation in
the amyloid precursor protein gene that results in a highly toxic
form of Ab (i.e., D-Ab40) which accumulates preferentially in brain
vessel walls and leads to severe cerebral hemorrhaging (Maat-
Schieman et al., 2005). Importantly, the presence of CAA does
correlate with cognitive decline of CAA-affected patients (Attems
et al., 2011; Greenberg et al., 2004). In general, 2 types of CAA
have been identiﬁed: type I CAA includes capillary Ab depositions in
addition to CAA in other cortical and leptomeningeal vessels,
whereas in type II CAA, capillary Ab depositions are not present
(Thal et al., 2002a). CAA is characterized by degeneration of smooth
muscle cells, disruption of the basement membrane, and remod-
eling of extracellular matrix (ECM) (Attems et al., 2011; Perlmutter
and Chui, 1990; Zipfel et al., 2009). Together, these alterations lead
to weakening of the vessel wall, impaired vascular functioning and,
ultimately, hemorrhages (Attems et al., 2011; Zipfel et al., 2009).
Despite the strong connection between cognitive decline, reduced
functioning of brain vasculature, and CAA, the factors and mecha-
nisms underlying accumulation and deposition of Ab in the vessel
wall remain largely unknown.
M. de Jager et al. / Neurobiology of Aging 34 (2013) 1159e11691160Tissue transglutaminase (tTG) is a member of the trans-
glutaminase family (TGs; EC 2.3.2.13) and is ubiquitously
expressed in the human brain (Kim et al., 1999; Wilhelmus et al.,
2009). tTG is a calcium-dependent enzyme involved in covalent
posttranslational modiﬁcations of proteins such as amine incor-
poration and molecular cross-linking (Lorand and Graham, 2003).
The latter is formed by the formation of a g-glutamyl-ε-lysine
bond between a glutamine residue and a lysine residue of
a peptide chain, which can be either intra- or intermolecular
(Fesus and Piacentini, 2002; Grifﬁn et al., 2002; Lorand and
Graham, 2003). This cross-linking activity provides tTG with the
powerful capacity to stably alter conformation of proteins and
induce formation of protein complexes (Lorand and Graham,
2003). An important biological role of this cross-linking activity
is formation of ECM protein complexes, which results in remod-
eling of the ECM in response to, e.g., cell stress and tissue injury
(Bakker et al., 2005; Grifﬁn et al., 2002; Ientile et al., 2007).
Evidence is mounting that tTG and its transamidation activity play
an important role in AD pathogenesis (Wilhelmus et al., 2008). In
AD brain, tTG levels and its cross-links are elevated (Appelt et al.,
1996; Johnson et al., 1997; Wang et al., 2008b) and correlate with
the cognitive decline observed in these patients (Sárvári et al.,
2002; Wang et al., 2008b). Furthermore, tTG binds to Ab, and
tTG-mediated cross-linking modulates the Ab aggregation
pathway (Dudek and Johnson, 1994; Ikura et al., 1993; Rasmussen
et al., 1994; Schmid et al., 2011). In fact, a recent study demon-
strated that tTG activity is able to induce formation of neurotoxic
and protease resistant Ab complexes at low, i.e., nanomolar,
concentrations of Ab (Hartley et al., 2008).
We recently demonstrated for the ﬁrst time that not only tTG,
but also tTG-mediated cross-links are associated with the patho-
logic hallmarks of AD (Wilhelmus et al., 2009). Interestingly, in this
study we found that tTG and its cross-links are associated with
both SPs and CAA; however, the distribution pattern of tTG and its
activity in both lesions appeared different (Wilhelmus et al., 2009).
In SPs, immunoreactivity of both tTG and its cross-links colo-
calized with the deposited Ab, in contrast to CAA where no spatial
overlay was observed. Instead, in CAA, tTG and its cross-links were
present as a luminal and abluminal halo which enclosed the
deposited Ab in middle-sized parenchymal vessels (Wilhelmus
et al., 2009). Remarkably, the tTG-immunoreactive halos that
surround the deposited Ab, resembled that of earlier immuno-
histochemical stainings of major ECM proteins (i.e., ﬁbronectinTable 1
Patient characteristics
Patient number Diagnosis Sex Age, y PMI (h) Grade (Braa
1 Control M 79 8 1
2 Control F 84 7 1
3 Control M 80 8 1
4 Control F 82 5 1
5 Control F 84 5 1
6 Control/CAA F 73 8 1
7 Control/CAA M 88 5 2
8 AD/CAA F 65 6 6
9 AD/CAA F 90 3 5
10 AD/capCAA F 81 3 6
11 AD/capCAA F 96 4 5
12 AD/CAA F 87 8 6
13 HCHWA-D F 60 5 1
14 HCHWA-D M 59 4 1
15 HCHWA-D F 51 4 0
16 HCHWA-D F 53 3 0
17 HCHWA-D F 53 6 1
Key: Ab, amyloid-beta; AD, Alzheimer’s disease; CAA, cerebral amyloid angiopathy; capC
with amyloidosis of the Dutch type; M, male; NFT, neuroﬁbrillary tangles; PMI, postmor
Grading of AD (Braak) and of CAA was performed as described in the Methods section.[FN] and laminin [LN]), and other known tTG substrates reported
by others (Miners et al., 2008; van Duinen et al., 1995; Zhang et al.,
1998). These results suggest a role for tTG-mediated ECM
remodeling in CAA which might be one of the unknown factors
that affect Ab deposition in the vessel wall and CAA development
(Wilhelmus et al., 2012).
To gain more insight into the role of tTG and its trans-
amidation activity in CAA, we studied the distribution pattern
and cellular source of tTG and its cross-links in different brain
vessels affected by CAA by use of immunoﬂuorescence on snap-
frozen brain tissue of AD, HCHWA-D, and control cases. In addi-
tion, we investigated colocalization of tTG and its cross-links with
ECM proteins, in particular the tTG substrates FN and LN (Grifﬁn
et al., 2002; Zemskov et al., 2006), in both AD and HCHWA-D
brains. Finally, we also investigated the distribution pattern and
overlay of in situ TG activity with CAA in control, AD, and
HCHWA-D cases.
2. Methods
2.1. Brain tissue
Human neocortex tissue samples from 5 AD patients with CAA,
including 2 patients with capillary CAA (age 83.8  11.8 years;
postmortem interval 8.0  2.2 hours) and 7 nondemented control
subjects without neurological disease including 2 control subjects
with CAA (age 81.4  4.7 years; postmortem interval 6.6  1.5
hours) were obtained from The Netherlands Brain Bank (Amster-
dam, The Netherlands). Brain tissue of the neocortex from 5
HCHWA-D patients (age 55.2  4.0 years; postmortem interval 4.4
 1.1 hours) was obtained from Dr S. van Duinen (Department of
Pathology, Leiden University Medical Centre, Leiden, The
Netherlands). After autopsy, samples were immediately frozen in
liquid nitrogen. Table 1 shows an overview of patient details
including sex, age, postmortem interval, diagnosis, cause of death,
Braak grading (for neuroﬁbrillary tangles and SPs), and CAA score.
The diagnosis of AD was based on neuropathologic and clinical
criteria (Braak et al., 2006; Thal et al., 2002b). CAA scoring was
performed as described previously (Wilhelmus et al., 2009): the
number of CAA-affected vessels of at least 4 microscopic ﬁelds
(magniﬁcation 4, 16mm2 permicroscopic ﬁeld) were counted and
classiﬁed as follows: 0 (-, no CAA),1e10 (þ, sparse CAA),11e20 (þþ,
moderate CAA) and > 21 (þþþ, severe CAA).k, NFTs) Grade (Braak, Ab) Grade (CAA) Cause of death
A - Pneumonia
O - Myelodysplasia
O - Not known
O - Not known
O - Heart failure
B þþ Palliative sedation
A þþþ Gastrointestinal bleeding
C þþ Pneumonia
C þþþ Cachexia
C þþþ Stroke
C þþþ Cachexia and dehydration
C þþþ Heart failure
- þþþ Cerebral hemorrhage
- þþþ Cerebral hemorrhage
- þþþ Cerebral hemorrhage
- þþþ Cerebral hemorrhage
- þþþ Cerebral hemorrhage
AA, capillary CAA; F, female; h, hours; HCHWA-D, hereditary cerebral hemorrhage
tem interval; y, years.
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Experiments were performed as described previously
(Wilhelmus et al., 2009, 2011a, 2011b). Serial sections of temporal
neocortex (6 mm) were ﬁxed with acetone (100%) for 10 minutes
and blocked with 3% bovine serum albumin (BSA; PAA Laboratories,
Pasching, Austria) in Tris buffered saline (TBS) with 0.5% Triton
X-100 (TBS-T). Negative controls were incubated in this solution
without the primary antibodies. Primary antibodies (Table 2) were
diluted in 3% BSA/TBS-T and incubated overnight at 4 C. After
washing with TBS, sections were incubated with the appropriate
secondary antibody. Secondary antibodies used were donkey anti-
mouse, donkey anti-goat, and donkey anti-rabbit, all coupled to
Alexa 488 or Alexa 594, (dilution 1:400, Invitrogen, Camarillo, CA,
USA). Biotin-labeled donkey anti-mouse-IgM (dilution 1:800,
Jackson Immunoresearch Laboratories Inc., West Grove, PA, USA)
was used for the tTG crosslink antibody (81D4) and staining was
enhanced with the Vectastain avidin-biotin kit (dilution 1:800 in
TBS-T, Vector Laboratories Inc., Burlingame, CA, USA). As a second
enhancement step for the 81D4 antibody, biotinylated tyramide in
0.005% H2O2-TBS was used (generous gift from Dr I. Huitinga,
Netherlands Institute for Neuroscience, Amsterdam, The
Netherlands). The conjugate streptavidin Alexa 488 (Invitrogen)
was used as a ﬂuorchrome for the 81D4 antibody; streptavidin
Alexa 594 was used as a secondary antibody for biotin-labeled
mouse anti-human Ab antibody. In between incubation steps,
sections were extensivelywashedwith TBS. Sections weremounted
with Vectashield (Vector Laboratories Inc.). The speciﬁcity of the
antibodies directed against tTG in human brain was demonstrated
in our previous reports (Wilhelmus et al., 2009, 2011b). The spec-
iﬁcity of the anti-TG catalyzed cross-link antibody was demon-
strated by preadsorption with H-Glu(H-Lys-OH)-OH (Bachem AG,
Bubendorf, Switzerland) in human brain tissue (Wilhelmus et al.,
2009). To visualize the ﬂuorescence stainings, a Leica TCS SP2
AOBS confocal laser scanning microscope (Leica Microsystems,
Rijswijk, The Netherlands) was used. To exclude false positive
ﬂuorescence signals for each channel, a series of images was ob-
tained separately in both channels through a 40 lens (zoom factor
1 to 4, Z-increment 0.15 mm, approximately 20 images of 512 
512 pixels).2.3. In situ TG activity
In situ TG activity detection was performed as described
previously (Jin et al., 2011), with some minor changes. In brief,
unﬁxed 6-mm thick tissue sections of neocortex of AD, HCHWA-D,
and control patients were preincubated for 30 minutes at room
temperature in a 100 mM Tris-HCl, pH 7.4, 5mM CaCl2, 1 mMTable 2
Primary antibodies
Antigen Primary antibody Species r
tTG Guinea pig tTG, Ab-1 Mouse
Guinea pig tTG (06471) Goat
Ab Human Ab biotinylated, clone 4G8 Mouse
Human Ab1e16 AB10 Mouse
Human Ab (715800) Rabbit
tTG cross-link H-Glu(H-Lys-OH)-OH, 81D4 Mouse
Astrocytes Bovine GFAP Rabbit
Endothelial cells Human Von Willebrand Factor Rabbit
Fibroblasts Vimentin Mouse
Smooth muscle cells Human smooth muscle actin Mouse
Fibronectin Mouse ﬁbronectin Rabbit
Laminin Mouse laminin Rabbit
Key: Ab, amyloid-beta; GFAP, glial ﬁbrillary acidic protein; tTG, tissue transglutaminase.dithiothreitol (Promega, Leiden, The Netherlands) buffer with or
without 100 mM of the tTG activity inhibitor Z-DON-Val-Pro-Leu-
OMe (Z-006) (Schaertl et al., 2010), purchased from Zedira GmbH,
Darmstadt, Germany. Then, incubation was continued for 40
minutes at 37 C with the same incubation buffer with or without
inhibitor to which 0.05 mM biotinylated 5-(biotinamido)-pentyl-
amine (BAP; Thermo Fisher Scientiﬁc, Fremont, CA, USA),
a substrate for TGs (Jeon et al., 1989; Lee et al., 1988), was added.
Thereafter, sections were washed with Milli-Q water, air-dried,
ﬁxed for 10 minutes with 100% acetone and subsequently incu-
bated with a primary antibody directed against tTG (Ab1, Neo-
markers) in 3% BSA/TBS-T for 1 hour at room temperature followed
by 1 hour incubation at room temperature with secondary anti-
bodies donkey anti-rabbit coupled to Alexa 594 to detect tTG
(dilution 1:400) and streptavidin coupled to Alexa 488 to detect
BAP incorporation (dilution 1:400). Sections were washed with TBS
in between and after antibody incubation and mounted with Vec-
tashield. The Leica TCS SP2 AOBS confocal laser scanning micro-
scope was used to visualize the staining as described above.3. Results
3.1. Distribution pattern of tTG and its cross-links in CAA of control,
AD, and HCHWA-D cases
The general staining pattern of tTG and TG-catalyzed cross-links
observed in theneocortexof control andADcases are in linewithour
previousﬁndings (Wilhelmus et al., 2009). Thus, in vessels of control
cases and non-CAA affected vessels in AD and HCHWA-D cases, tTG
stainingwas present in all layers of the vesselwall in leptomeningeal
and parenchymal vessels (Fig. 1AeC, arrow), and in capillaries. In
addition, weak anti-tTG cross-link immunoreactivity was observed
in all layers of the vessel wall in leptomeningeal and parenchymal
vessels, predominantly at the endothelial side of the vessel wall (not
shown). In CAA of AD cases, no spatial overlay of anti-tTG immu-
noreactivity with anti-Ab staining was observed (Fig. 1AeC).
However, tTG staining was present as a halo at both the luminal and
abluminal side of deposited Ab, in parenchymal vessels (Fig. 1AeC),
leptomeningeal vessels (Fig. 1DeF), and in capillaries (Fig. 1GeI).
Similar to tTG immunoreactivity in CAA, tTG cross-link staining was
present in an abluminal and/or luminal halo surrounding Ab depo-
sition in leptomeningeal and parenchymal vessels (Fig. 1JeL), but
only in an abluminal halo in capillary CAA (Fig. 1MeO). In CAA
present in nondemented control cases, a similar staining pattern for
both tTG and its cross-linkswas observed (not shown). Interestingly,
in probable CAA precursors, observed in the form of local Ab depo-
sition in a largeparenchymal vessel (Fig. 2AeC) and a capillary vessel
(Fig. 2DeF) of AD cases, anti-tTG immunoreactivity was elevatedaised in Dilution Company
1:300 Thermo Fisher Scientiﬁc, Fremont, CA, USA
1:4000 Millipore, Temecula, CA, USA
1:400 Covance, Emeryville, CA, USA
1:200 Millipore, Temecula, CA, USA
1:100 Invitrogen, Camarillo, CA, USA
1:100 Covalab, Villeurbanne, France
1:2000 Dako Cytomation, Glostrup, Denmark
1:500 Dako Cytomation, Glostrup, Denmark
1:2000 Dako Cytomation, Glostrup, Denmark
1:200 Dako Cytomation, Glostrup, Denmark
1:400 Millipore, Temecula, CA, USA
1:100 Cappel, Solon, Ohio, USA
Fig. 1. Double immunoﬂuorescence staining of tissue transglutaminase (tTG) and tTG cross-links in cerebral amyloid angiopathy (CAA) in neocortex of Alzheimer’s disease cases. The
anti-amyloid-beta (Ab) antibody (715800) stained Ab deposition in CAA-affected vessels (B, E, H, K, N). Double immunoﬂuorescence staining of the anti-Ab antibody with either the
anti-tTG (Ab1) or anti- transglutaminase-catalyzed cross-link antibody was performed. In Alzheimer’s disease cases, tTG staining was observed in control vessels (A, arrow). In CAA
however, tTG staining was observed in an abluminal and luminal halo enclosing the Ab deposition in both parenchymal (AeC) and leptomeningeal (DeF) vessels. In capillary CAA,
tTG (Ab1 antibody) was present in an abluminal halo (GeI). Anti-tTG cross-link immunoreactivity was present at the abluminal and luminal side of the Ab deposition in larger
cortical vessels (JeL) and at the abluminal side of capillary CAA (MeO). Scale bars: B, E, H, K, and N, 30 mm.
M. de Jager et al. / Neurobiology of Aging 34 (2013) 1159e11691162compared with the unaffected part of the vessel, and, in contrast to
the fully developed CAA, spatially colocalizedwith the deposited Ab.
To investigate whether the appearance of tTG and its cross-links as
halos surrounding CAAmight be a general phenomenon in CAA, weperformed the above-described stainings inHCHWA-Dpatients. The
distribution of tTG (Fig. 3) and cross-links (not shown) in CAA in
HCHWA-D cases was similar to CAA in AD cases, although tTG
staining was more intense as compared with AD.
Fig. 2. Double immunoﬂuorescence staining of tissue transglutaminase (tTG) with amyloid-beta (Ab) in vessels partly affected by Ab deposition. In a large parenchymal vessel (AeC)
and capillary vessel (DeF), the anti-Ab antibody (AB10 and 715800, respectively) stained the Ab deposition (B and E). The anti-tTG antibody (06471 and Ab-1, respectively) showed
a strong immunoreactivity in the Ab-affected part of the vessel compared with the nonaffected part of the blood vessel. In addition, tTG staining colocalized with the Ab staining
(AeF, arrows). Scale bars: B, 30 mm; E, 15 mm.
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To investigate the cellular origin of the observed tTG staining
enclosing the deposited Ab in CAA, double immunoﬂuorescence
staining of tTG with cell-speciﬁc markers (glial ﬁbrillary acidic
protein, [GFAP] for astrocytes, Sofroniew and Vinters, 2010; von
Willebrand Factor [VWF] for endothelial cells, Girma et al., 1987,
Jaffe et al., 1974; vimentin for ﬁbroblasts, Franke et al., 1978; and
smooth muscle actin [SMA] for smooth muscle cells, Skalli et al.,
1987) was performed. Control cases, weak tTG staining was
observed in astrocytes associated with brain vessels (Fig. 4AeC). In
CAA of AD cases however, strong anti-tTG immunoreactivity was
observed in GFAP-positive astrocytes at the abluminal side of CAA
in parenchymal vessels (Fig. 4DeF). Especially the astrocytic end
feet demonstrated strong tTG staining in CAA (Fig. 4DeF). In CAA of
leptomeningeal vessels tTG colocalized partly with vimentin,
a marker for ﬁbroblasts, in the abluminal halo (Fig. 4GeI). Double
immunoﬂuorescence staining of tTG immunoreactivity with the
anti-VWF antibody in control cases and in non-CAA affected vessels
of AD cases, demonstrated tTG staining in all layers of the vessel
wall, which at the luminal side colocalized with endothelial cells
(not shown). In CAA of AD cases the luminal halo of tTG colocalizedFig. 3. Double immunoﬂuorescence staining of tissue transglutaminase (tTG) in cerebral amy
of the Dutch type cases. The anti-amyloid-beta (Ab) antibody (4G8) stained Ab deposition in
(Ab1) antibody was performed. In CAA, tTG staining was observed in an abluminal and lumwith endothelial cells, in both parenchymal (Fig. 4JeL) and lep-
tomeningeal vessels (not shown). SMA staining was present in all
layers of the vessel wall in control vessels where it colocalized with
tTG (not shown). However, although SMA staining was present in
all layers of vessels affected by CAA, no colocalization with tTG was
observed (Fig. 4MeO).
In HCHWA-D cases, like the AD staining, tTG and its cross-links
colocalized with the astrocyte marker GFAP in astrocytic end feet at
the abluminal side of Ab in parenchymal vessels, and with the
endothelial marker VWF at the luminal side of Ab (not shown).
3.3. Colocalization of tTG and its cross-links with ECM proteins in
CAA of AD cases
tTG plays an important role in modulation of the ECM by cross-
linking of ECM proteins (Grifﬁn et al., 2002; Zemskov et al., 2006).
As demonstrated previously, several ECM proteins are associated
with CAA, but do not spatially colocalize with the actual Ab depo-
sition itself (Miners et al., 2008; van Duinen et al., 1995; Zhang et al.,
1998). Interestingly, the staining pattern of these ECM proteins
resembles that of tTG and cross-links in CAA, as described in this
study. Together, these data suggested that tTG might cross-link theloid angiopathy (CAA) in neocortex of hereditary cerebral hemorrhage with amyloidosis
CAA (B). Double immunoﬂuorescence staining of the anti-Ab antibody with the anti-tTG
inal halo enclosing the Ab deposition (AeC). Scale bar: B, 30 mm.
Fig. 4. Double immunoﬂuorescence staining of tissue transglutaminase (tTG) with cellular markers in cerebral amyloid angiopathy (CAA) in control and Alzheimer's disease cases.
The anti-glial ﬁbrillary acidic protein (GFAP) antibody stained astrocytes in parenchymal vessels (B and E), whereas the anti-vimentin antibody stained ﬁbroblasts in the adventitia
of the vessel wall of leptomeningeal vessels (H). The anti-Von Willebrand Factor (VWF) antibody stained endothelial cells in blood vessels (K) and the anti-smooth muscle actin
(SMA) antibody stained smooth muscle cells in the media of the vessel wall (N). Double immunoﬂuorescence staining of the anti-tTG (Ab1) antibody with either the anti-GFAP or
anti-VWF antibody and double immunoﬂuorescence of the anti-tTG (06471) antibody with either the anti-vimentin or anti-SMA antibody was performed. In control vessels,
sporadic colocalization of tTG staining with GFAP staining was observed (AeC). In parenchymal CAA vessels, tTG staining in the abluminal halo (D) colocalized with the GFAP
staining in astrocytic end feet (E and F). In leptomeningeal CAA vessels, tTG in the abluminal halo (G) colocalized with the vimentin staining (H and I, arrow). The tTG staining in the
luminal halo (J) in CAA vessels colocalized with the anti-VWF antibody (K and L). tTG in the abluminal and luminal halo surrounding CAA did not spatially colocalize with SMA
staining (MeO). Scale bars: B, H, K, and N, 30 mm; E, 15 mm.
M. de Jager et al. / Neurobiology of Aging 34 (2013) 1159e11691164ECM in CAA. We therefore performed double immunoﬂuorescence
staining of tTG and cross-links with antibodies directed against the
ECM proteins FN and LN, which are well-known tTG substrates
(Grifﬁn et al., 2002; Zemskov et al., 2006). In vessels of control casesand nonaffected vessels in AD cases, FN and LN were present in all
layers of the vessel wall of leptomeningeal and parenchymal blood
vessels, and in capillaries (not shown). These data are in line with
previous reports (Colognato and Yurchenco, 2000; Stenman and
M. de Jager et al. / Neurobiology of Aging 34 (2013) 1159e1169 1165Vaheri, 1978). In CAA in AD cases, elevated anti-FN and anti-LN
immunoreactivity was found as an abluminal and/or luminal halo
enclosing the deposited Ab (Fig. 5B and E). In addition, both the
anti-FN and anti-LN immunoreactivity colocalized with tTG
(Fig. 5AeC and DeF, respectively) and tTG cross-link staining
(Fig. 6AeC and DeF, respectively). In CAA of HCHWA-D cases, the
distribution of FN and LN staining was similar to the AD cases,
showing an abluminal and/or luminal halo that spatially colocalized
with the anti-tTG antibody (Fig. 5GeI and JeL, respectively).
3.4. In situ TG activity in CAA in AD and HCHWA-D cases
We observed that tTG staining was present in the Ab part of CAA
precursors, whereas in later stages of CAA, tTG was not present in
the Ab deposition. Epitope masking of tTG might have caused this
lack of staining. In addition, the conformation of tTG, which is an
important property of the enzyme that inﬂuences its function
(Pinkas et al., 2007), might affect the recognition by the antibodiesFig. 5. Double immunoﬂuorescence staining of tissue transglutaminase (tTG) with extracellu
hereditary cerebral hemorrhage with amyloidosis of the Dutch type (HCHWA-D) cases. Doub
anti-laminin (LN) antibody with the anti-tTG antibody (Ab1). In CAA vessels of AD patients, F
and/or luminal halo enclosing the amyloid-beta deposition. The same staining pattern was o
enclosing the amyloid-beta deposition, colocalizing with the tTG staining (GeI). Also anti-LN
beta deposition, and colocalized with the tTG staining (JeL). Scale bars: B, E, H, and K, 30 mwe used. Therefore, to investigate whether tTG is still present and
active in the Ab part of CAA, we investigated the in situ activity of
TGs by the incorporation of the TG substrate BAP. Snap frozen tissue
sections of the neocortex of AD, HCHWA-D, and control cases were
incubatedwith the TG substrate BAP and stained for the presence of
tTG and BAP. In vessels of control cases and non-CAA affected
vessels in AD and HCHWA-D cases, weak BAP stainingwas observed
in all layers of the vessel wall which colocalized with tTG staining
(Fig. 7AeC). After coincubation with the speciﬁc tTG inhibitor
Z-006, no BAP staining was detectable, in contrast to the tTG
staining, which remained unaffected (Fig. 7DeF). In CAA in AD and
HCHWA-D cases, however, BAP staining was remarkably increased
compared with control vessels, and was present in all layers of the
vessel wall (Fig. 7G). In addition, BAP staining also colocalized with
the typical tTG halos enclosing the Ab part of CAA (Fig. 7GeI,
arrow). After coincubation with the speciﬁc tTG inhibitor Z-006, no
BAP staining was detectable in CAA, whereas tTG staining was still
present in the two halos surrounding the deposited Ab (Fig. 7JeL).lar matrix proteins in cerebral amyloid angiopathy (CAA) in Alzeimer’s disease (AD) and
le immunoﬂuorescence staining was performed with either the anti-ﬁbronectin (FN) or
N and LN staining colocalized with the tTG staining (FN: AeC, LN: DeF) in an abluminal
bserved in HCHWA-D cases. FN staining was observed in an abluminal and luminal halo
immunoreactivity was present in an abluminal and luminal halo enclosing the amyloid-
m.
Fig. 6. Double immunoﬂuorescence staining of tissue transglutaminase (tTG) cross-links with extracellular matrix proteins in cerebral amyloid angiopathy (CAA) in Alzheimer’s
disease cases. Double immunoﬂuorescence staining was performed with either the anti-ﬁbronectin (FN) or anti-laminin (LN) antibody with the anti-tTG cross-link antibody. In CAA
vessels of Alzheimer’s disease cases, FN and LN staining colocalized with the tTG cross-link staining (FN: AeC; LN: DeF) in an abluminal and/or luminal halo enclosing the amyloid-
beta deposition. Scale bars: B and E, 30 mm.
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In this study, we describe for the ﬁrst time that immunoreac-
tivity of tTG in a vessel wall partly affected by Ab deposition, which
might indicate an early stage, is increased and colocalizes with the
deposited Ab. In contrast, in later stages of CAA, both tTG and its
cross-links no longer colocalize with the deposited Ab, but are
present in an abluminal and luminal halo enclosing the Ab depo-
sition. We observed that the abluminal halo of parenchymal vessels
in CAA are of astrocytic origin and that tTG might derive from
ﬁbroblasts in leptomeningeal vessels, whereas tTG in the luminal
halo in all vessel types is of endothelial origin. Furthermore, tTG
substrates and important ECM components FN and LN colocalize
with tTG and its cross-links in the halos that enclose Ab deposition
in CAA. We observed this distribution pattern of tTG and its cross-
links in CAA in nondemented control, AD, and HCHWA-D cases,
which suggests that this pattern is a general phenomenon of CAA.
Surprisingly however, although we did not observe tTG and tTG
cross-link staining in the actual Ab deposition in CAA, we found that
tTG is still present and could be activated in situ in the deposited Ab.
Together our data suggest that tTG plays a unique role in CAA
development and progression. Initially, tTG levels are elevated in
early stages of CAA, andmight even precede Ab deposition, whereas
in later stages tTG is likely to be involved in alteration and/or
remodeling of the ECM in CAA.
Previously, we noticed an important discrepancy between the
distribution pattern of tTG and its cross-links in SPs and CAA. tTG
and its cross-links colocalized with the deposited Ab in both diffuse
and classic SPs, whereas in CAA, tTG and its cross-links did not
colocalize with the Ab aggregate itself (Wilhelmus et al., 2009).
Instead, in CAA, both tTG and its cross-links were present in an
abluminal and luminal halo enclosing the Ab deposition in middle-
sized parenchymal vessels with CAA in AD patients (Wilhelmus
et al., 2009). In the present study, we found that apart from
middle-sized parenchymal vessels affected by CAA in AD cases, tTG
and its cross-links enclose the Ab deposition in all parenchymal
vessels and leptomeningeal vessels, as well as in capillaries affected
by CAA. In addition, tTG and its cross-links were present in a similardistribution pattern in CAA in HCHWA-D cases and in CAA-affected
vessels of nondemented control cases. Together, these ﬁndings
point out that the presence of tTG and cross-links in halos that
enclose Ab is a common phenomenon found in type I and type II
CAA (with or without capillary CAA respectively), in different
diseases that are characterized by CAA, and even in CAA in non-
demented control cases.
Interestingly, in a parenchymal and capillary vessel only partly
affected by CAA, which might indicate an early stage of CAA
development, tTG was present in the Ab deposition itself. In later
stages of CAA, tTG and its cross-links did not colocalize with Ab,
although tTG could still be activated with our in situ assay in both
the Ab part of CAA and the tTG-immunoreactive halos enclosing the
Ab. However, it should be noted that although it is highly likely that
our in situ approach demonstrates tTG activity, this technique
might also activate other TGs. However, although both TG1 and TG3
are present in the human brain, there is no association of these TGs
with cerebral vessels or CAA (Kim et al., 1999; Wilhelmus et al.,
2009). In addition, the potent tTG inhibitor Z-006 that was used
in our experiments could inhibit other TGs, yet it has a signiﬁcantly
higher afﬁnity for tTG compared with other TGs (Schaertl et al.,
2010). Together we therefore conclude that tTG is present in CAA
in early and later stages and that its activity might have a unique
role in Ab deposition and development of CAA.
In early stages of CAA development, Ab accumulates in the
media around the vascular smooth muscle cells (Attems et al.,
2011). We observed tTG immunostaining in the Ab deposition
itself in vessels partly affected by CAA. In this stage of CAA, tTG
might originate from smooth muscle cells, because these cells are
known to produce and secrete tTG (Greenberg et al., 1991; van den
Akker et al., 2012). A similar tTG staining was present in capillaries
suggesting that pericytes are the cellular source in capillaries.
Hence, endothelial cells are also known to produce tTG (Thomazy
and Fesus, 1989). Although the cellular origin of tTG in capillaries
and larger vessels might differ, tTG staining in the Ab deposition
was increased compared with the non-CAA affected part of the
vessel wall. This suggests that either tTG levels are elevated in
response to the Ab deposition in the vessel wall, or that induced tTG
Fig. 7. In situ transglutaminase activity. Double immunoﬂuorescence was performed with the anti-tissue transglutaminase (tTG) antibody (Ab1) and streptavidin coupled to Alexa
488 directed against the biotin-label of biotinylated 5-(biotinamido)-pentylamine (BAP). In non-cerebral amyloid angiopathy (non-CAA) vessels of Alzheimer’s disease cases, weak
staining of both BAP and tTG was observed in all layers of the vessel wall (AeC). In addition, BAP and tTG staining colocalized in all layers of the vessel wall (AeC). Coincubation of
the speciﬁc tTG inhibitor Z-006 (100 mM) with BAP resulted in absence of BAP staining in the control vessel (D). In cerebral amyloid angiopathy (CAA), strong BAP staining was
observed in all layers of the vessel wall (G), whereas no BAP staining was present after coincubation with Z-006 (100 mM) (J). tTG was again present in an abluminal and luminal halo
surrounding the amyloid-beta deposition in CAA (H and K). Colocalization of BAP with tTG staining was observed in CAA (GeI, arrows). Scale bar: B and E, 15 mm; H and K, 30 mm.
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in vitro study has shown that tTG is upregulated in a monocytic cell
line after treatment with Ab1e42 (Curro et al., 2010). Furthermore,
tTG can cross-link Ab and affect its aggregation pathway (Dudek
and Johnson, 1994; Hartley et al., 2008; Ikura et al., 1993;
Rasmussen et al., 1994; Schmid et al., 2011). Therefore, in vivo tTG
expression might be increased in response to Ab deposition in the
vessel wall, whichmight lead to Ab cross-linking in the initial stages
of CAA. On the contrary, increased levels of tTG might also precede
Ab deposition. tTG is normally present in the vessel wall, where it is
important in cross-linking of ECM proteins leading to remodeling of
the vessel wall (Bakker et al., 2005). Levels of tTG in the vasculature
increase with age, which leads to enhanced ECM cross-linking and
subsequent vascular stiffness (Santhanam et al., 2010). These
changes in the vessel wall might inﬂuence Ab deposition. In addi-
tion, several proteins that are known to affect the Ab cascade, in
particular heparan sulphate proteoglycans and small heat shock
protein B2 (Wilhelmus et al., 2006, 2007), are also substrates for
tTG (Boros et al., 2006; Verderio et al., 2009). The fact that these tTGsubstrates are present in CAA as well suggests that tTG activity
might affect Ab aggregation and deposition, either directly or via
cross-linking of Ab chaperones. However, the role of tTG in initial
stages of CAA remains to be investigated, and the use of in vivo
models, in particular animalmodels of CAA, will be instrumental for
this purpose.
In late stages of CAA, we found that tTG staining in the abluminal
halo was of astrocytic origin in parenchymal vessel and derived
from ﬁbroblasts in leptomeningeal vessels, whereas tTG was of
endothelial origin in the luminal halo. All these cell types are
known to produce tTG (Bakker et al., 2008; Nurminskaya and
Belkin, 2012; Yamada et al., 1998; Zemskov et al., 2006), and tTG
is upregulated in response to cell stress and inﬂammation (Wang
et al., 2008a). Ab deposition is suggested to precede inﬂammation
(Heneka et al., 2010), thus expression of tTG might be increased
especially in the cells surrounding the Ab deposition in CAA. In
parenchymal vessels, ﬁbroblasts might produce tTG as well,
although we could not distinguish astrocytes from ﬁbroblasts, as
vimentin stains mesenchymal cells including astrocytes and
M. de Jager et al. / Neurobiology of Aging 34 (2013) 1159e11691168ﬁbroblasts. Taken together, although the tTG in CAA is likely to be
derived from astrocytes, ﬁbroblasts, and endothelial cells, a role in
the production of tTG by smooth muscle cells, as in early stage CAA,
cannot be excluded.
The presence and activity of tTG in the abluminal and luminal
halo points toward a role in remodeling of the ECM. Altered
expression of ECM proteins has already been observed in CAA and
the brain microvasculature in AD (Kalaria, 1996; Miners et al., 2008;
Perlmutter, 1994; Perlmutter and Chui, 1990; van Duinen et al.,
1995; Zhang et al., 1998). In our study we observed, in line with
previous studies (Miners et al., 2008; van Duinen et al., 1995; Zhang
et al., 1998), altered expression of the ECM proteins FN and LN. Both
FN and LN were present in an abluminal and/or luminal halo that
surrounded the Ab deposition. We here found that FN and LN
colocalized with tTG and its cross-links in CAA of AD and HCHWA-D
patients, suggesting that tTGmight cross-link these ECMproteins in
CAA. The putative cross-linking of FN and LN by tTG might have
detrimental effects, because excess production and cross-linking of
ECM proteins in diabetic nephropathy is associated with renal
ﬁbrosis and scarring (Skill et al., 2004). Furthermore, the formation
of cross-linked proteins at the endothelial side of the vessel could
impair transport of solutes and molecules across the blood-brain
barrier leading to impaired supply of nutrients in the brain thus
compromising brain functioning. In addition, tTG-mediated cross-
linking of ECM proteins might stiffen the vessel wall, resulting in
impaired clearance of Ab from the brain via the interstitial ﬂuid
drainage (Schley et al., 2006; Weller et al., 2009; Wilhelmus et al.,
2012). Furthermore, impaired clearance of Ab via this route might
not only be the underlying cause of Ab accumulation in the vessel
wall leading to CAA, but also contributes to the accumulation of Ab
in the brain parenchyma (Weller et al., 2009).
On the other hand, the cross-linked ECM proteins might have
a protective effect in CAA, because this cross-linked barrier might
prevent the weakening of the vessel wall (Zipfel et al., 2009) and
leakage of the blood-brain barrier, possibly reducing the risk of
hemorrhages which can be the result of CAA (Attems et al., 2011;
Wisniewski et al., 1997; Zipfel et al., 2009). In addition, at the
abluminal side, the cross-linked ECM proteins might serve as
a barrier to prevent spreading of toxic Ab into the brain paren-
chyma. Clearly, further investigations are required to investigate
these options.
In conclusion, we found that tTG immunoreactivity is increased
in early stages of CAAwhere it colocalized with Ab deposition in the
vessel wall, whereas tTG and its cross-links in more mature CAA
lesions colocalized with ECM proteins in an abluminal and luminal
halo enclosing the Ab deposition. The role of tTG in early stage CAA
might therefore be different from end stage CAA, when tTG-
mediated ECM remodeling might be more important than its
effect on Ab aggregation per se. However, because we observed an
increased tTG transamidation activity in the Ab deposition also in
end stage CAA lesions, this might be the consequence of epitope
masking in these densely packed Ab depositions. Chronological
evaluation of CAA lesion development in animal models of CAAwill
hopefully provide answers to the outstanding questions on the role
of tTG in vascular pathology in AD and related disorders.Disclosure statement
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